Literature DB >> 25979578

Multiple sclerosis.

Daniel Kane Files1, Tani Jausurawong1, Ruba Katrajian1, Robert Danoff2.   

Abstract

Multiple sclerosis (MS) is a chronic, debilitating disease that can have devastating effects. Presentation varies widely in symptoms, pace, and progression. In addition to a thorough history and physical examination, diagnostic tools required to diagnose MS and exclude other diagnoses include MRI, evoked potential testing, and cerebrospinal fluid analysis. Although the disease is not curable presently, quality of life can be improved by minimizing the frequency and severity of disease burden. Disease modification, symptom management, preservation of function, and treatment of psychosocial issues are paramount to enhance the quality of life for the patient affected with MS.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epstein–Barr virus; Latitude; Multiple sclerosis; Vitamin D

Mesh:

Substances:

Year:  2015        PMID: 25979578     DOI: 10.1016/j.pop.2015.01.007

Source DB:  PubMed          Journal:  Prim Care        ISSN: 0095-4543            Impact factor:   2.907


  12 in total

Review 1.  Advancing drug delivery systems for the treatment of multiple sclerosis.

Authors:  Inna Tabansky; Mark D Messina; Catherine Bangeranye; Jeffrey Goldstein; Karen M Blitz-Shabbir; Suly Machado; Venkatesh Jeganathan; Paul Wright; Souhel Najjar; Yonghao Cao; Warren Sands; Derin B Keskin; Joel N H Stern
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

2.  Self-reported changes in the expanded disability status scale score in patients with multiple sclerosis after autologous stem cell transplants: real-world data from a single center.

Authors:  G J Ruiz-Argüelles; J C Olivares-Gazca; M Olivares-Gazca; A A Leon-Peña; I Murrieta-Alvarez; Y Cantero-Fortiz; G B Gomez-Cruz; A Ruiz-Argüelles; M Priesca-Marin; G J Ruiz-Delgado
Journal:  Clin Exp Immunol       Date:  2019-08-19       Impact factor: 4.330

3.  Validity and Reliability of the Turkish Version of the Monitoring My Multiple Sclerosis Scale.

Authors:  Cansu Polat; Zeliha Tülek; Murat Kürtüncü; Mefkure Eraksoy
Journal:  Noro Psikiyatr Ars       Date:  2017-01-19       Impact factor: 1.339

4.  HLA-DRB1*15 association with multiple sclerosis is confirmed in a multigenerational Italian family.

Authors:  L Mosca; V Mantero; S Penco; L La Mantia; S De Benedetti; M R Marazzi; C Spreafico; C Erminio; L Grassi; G Lando; M Zagaria; E Agostoni; A Protti
Journal:  Funct Neurol       Date:  2017 Apr/Jun

5.  Surfactant protein A is expressed in the central nervous system of rats with experimental autoimmune encephalomyelitis, and suppresses inflammation in human astrocytes and microglia.

Authors:  Xue Yang; Jun Yan; Juan Feng
Journal:  Mol Med Rep       Date:  2017-04-07       Impact factor: 2.952

6.  Multi-drug use among patients with multiple sclerosis: A cross-sectional study of associations to clinicodemographic factors.

Authors:  Niklas Frahm; Michael Hecker; Uwe Klaus Zettl
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

7.  A narrative review of psoriasis and multiple sclerosis: links and risks.

Authors:  Annika S Silfvast-Kaiser; Katie B Homan; Bobbak Mansouri
Journal:  Psoriasis (Auckl)       Date:  2019-08-22

Review 8.  Prevalence of familial multiple sclerosis in Iran: A systematic review and meta-analysis.

Authors:  Mahmood Moosazadeh; Ravanbakhsh Esmaeili; Mohammad Mehdi Nasehi; Ghasem Abedi; Mahdi Afshari; Fereshteh Farshidi; Motahareh Kheradmand
Journal:  Iran J Neurol       Date:  2017-04-04

9.  Monitoring interferon β treatment response with magnetic resonance spectroscopy in relapsing remitting multiple sclerosis.

Authors:  Mehmet Fatih Yetkin; Meral Mirza; Halil Dönmez
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

10.  Psychosocial and Medical Determinants of Health-related Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis.

Authors:  Isaac Rahimian Boogar; Siavash Talepasand; Mohammad Jabari
Journal:  Noro Psikiyatr Ars       Date:  2018-03-19       Impact factor: 1.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.